LIVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LivaNova PLC (LIVN) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available. The company's innovative developments in the medical field, particularly the PolySync algorithm and upcoming MRI-compatible OSA device, present strong growth potential. Despite the lack of recent Intellectia trading signals, the technical indicators are bullish, and analysts maintain positive ratings with raised price targets. The stock is well-positioned for long-term growth.
The MACD histogram is positive at 0.0879, indicating bullish momentum. RSI is neutral at 60.691, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels suggest a pivot at 76.949, with resistance at 80.343 and support at 73.555. Overall, the technical indicators are favorable for a long-term buy.
PolySync algorithm significantly improves treatment outcomes for Obstructive Sleep Apnea (OSA), increasing response rates to 84.5%.
Plans to submit a PMA supplement for an MRI-compatible OSA device in late 2026, showcasing innovation and growth potential.
Analysts have raised price targets, reflecting confidence in the company's future performance.
Post-market price decline of -1.33%, which may indicate short-term selling pressure.
Neutral trading sentiment from hedge funds and insiders, with no significant recent activity.
No financial data available for analysis.
Analysts maintain positive ratings with recent price target adjustments. Mizuho raised the target to $90 (Outperform), Baird adjusted to $76 (Outperform), and Barclays increased to $76 (Equal Weight). These updates reflect optimism following strong Q1 results and portfolio strength.
